Last update 01 Nov 2024

TT-01488

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
BTK
Mechanism
BTK inhibitors(Tyrosine-protein kinase BTK inhibitors)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [2]
Active Indication
B-Cell Malignant NeoplasmB-Cell LymphomaChronic Lymphocytic Leukemia+ [2]
Inactive Indication-
Originator Organization
TransThera Sciences (Nanjing), Inc.TransThera Sciences (Nanjing), Inc.Startup
Active Organization
TransThera Sciences (Nanjing), Inc.TransThera Sciences (Nanjing), Inc.Startup
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with TT-01488
NCT05683717 / RecruitingPhase 1
A Phase I, Multicenter, Open Label, and Dose-Escalation Study of TT-01488, Administered Orally in Adult Patients With B-Cell Malignancies
CTR20223038 / RecruitingPhase 1
B细胞恶性肿瘤成年受试者口服TT-01488的多中心、剂量递增、开放性I期临床试验
[Translation] A multicenter, dose-escalation, open-label Phase I clinical trial of oral TT-01488 in adult subjects with B-cell malignancies
NCT05275504 / RecruitingPhase 1
A Phase I, First-In-Human, Multicenter, Open Label, and Dose-Escalation Study of TT-01488, Administered Orally in Adult Patients With B-Cell Malignancies
100 Clinical Results associated with TT-01488
Login to view more data
100 Translational Medicine associated with TT-01488
Login to view more data
100 Patents (Medical) associated with TT-01488
Login to view more data
100 Deals associated with TT-01488
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
B-Cell Malignant NeoplasmPhase 1
CN
TransThera Sciences (Nanjing), Inc.TransThera Sciences (Nanjing), Inc.Startup
24 Mar 2023
B-Cell LymphomaPhase 1
US
TransThera Sciences (Nanjing), Inc.TransThera Sciences (Nanjing), Inc.Startup
01 Jun 2022
Chronic Lymphocytic LeukemiaIND Approval
CN
TransThera Sciences (Nanjing), Inc.TransThera Sciences (Nanjing), Inc.Startup
19 Apr 2022
Mantle-Cell LymphomaIND Approval
CN
TransThera Sciences (Nanjing), Inc.TransThera Sciences (Nanjing), Inc.Startup
19 Apr 2022
Waldenstrom MacroglobulinemiaIND Approval
CN
TransThera Sciences (Nanjing), Inc.TransThera Sciences (Nanjing), Inc.Startup
19 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free